Focused On-demand Library for Mitogen-activated protein kinase 14

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Cytokine suppressive anti-inflammatory drug-binding protein; MAP kinase MXI2; MAX-interacting protein 2; Mitogen-activated protein kinase p38 alpha; Stress-activated protein kinase 2a

Alternative UPACC:

Q16539; A6ZJ92; A8K6P4; B0LPH0; B5TY32; O60776; Q13083; Q14084; Q8TDX0


Mitogen-activated protein kinase 14 (MAPK14), also known as p38 alpha, plays a pivotal role in the MAP kinase signal transduction pathway. It is activated by various extracellular stimuli, leading to the phosphorylation of numerous substrates involved in inflammatory responses, stress, and mitogenic stimuli. MAPK14's interaction with kinases and transcription factors facilitates immediate-early gene induction, protein synthesis regulation, and apoptosis inhibition.

Therapeutic significance:

Understanding the role of Mitogen-activated protein kinase 14 could open doors to potential therapeutic strategies. Its involvement in key cellular processes such as inflammation, stress response, and cell proliferation makes it a promising target for drug discovery efforts aimed at treating related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.